In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.